UTMB has been awarded an agreement up to nearly $25 million from the U.S. Department of Defense’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) (within the Administration for Strategic Preparedness and Response (ASPR)), for their efforts in the collaborative development of vaccines to protect against infection by Ebola (EBOV), Sudan (SUDV), Marburg (MARV), and Lassa (LASV) viruses. This project award was executed via Other Transaction Authority (OTA) to UTMB through the Medical CBRN Defense Consortium (MCDC).
Surgeons at UTMB Health’s Clear Lake Campus recently performed the hospital’s first craniotomy for brain tumor removal and the first intracranial aneurysm clipping, which represent an expansion of services offered at the campus as the hospital continues to find new and innovative ways to provide world-class treatments to the growing communities it serves.